April 15, 2026
There is enough evidence from which a jury could conclude that Amneal Pharmaceuticals participated in a conspiracy to fix the price of an epilepsy medication, but not enough to show it participated in the overarching antitrust conspiracy alleged by dozens of state attorneys general, a Connecticut federal judge ruled Wednesday.
April 14, 2026
A Connecticut federal judge Tuesday denied a request by dozens of U.S. states to freeze their antitrust case against generic-drug manufacturers, a pause the states argued would allow the parties to focus on settlement talks rather than pending discovery and motion deadlines.
April 09, 2026
An Irish entity of drugmaker Mallinckrodt waited too long to seek dismissal of a price-fixing lawsuit brought by states based on a lack of personal jurisdiction or proper service, a Connecticut federal judge has ruled, finding that the company first raised that argument more than five years after the complaint was filed.
April 08, 2026
The states suing generic-drug manufacturers in one of three sprawling antitrust cases want a Connecticut federal judge to pause all deadlines for three months so they can focus on settling with the remaining defendants, according to a joint filing.
March 04, 2026
Purchasers of certain generic drugs asked a Pennsylvania federal court for final approval of settlements worth a total of at least $58 million with Glenmark Pharmaceutical Inc., Greenstone LLC and Pfizer Inc. over claims the companies colluded with others to keep drug prices high.
March 02, 2026
Solar panel co. PosiGen was given the green light to wind down, fiber network Tilson's Chapter 11 case was dismissed, and Mallinckrodt's bankruptcy prevented antitrust payouts.
February 26, 2026
Sun Pharmaceutical and Taro Pharmaceuticals can use their $200 million settlement with the "end payors" for generic drugs in an alleged price-fixing scheme as a defense in a similar lawsuit brought by 47 states and territories, the Connecticut federal judge overseeing the case ruled Wednesday.
February 25, 2026
A Connecticut federal judge on Wednesday advanced a $17.9 million generic drug price-fixing settlement between 48 states and territories and pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc. and Lannett Co. Inc., sidelining objections by consumers suing separately in a Pennsylvania multidistrict litigation case.
February 24, 2026
A Connecticut federal judge has ruled that drugmaker Mallinckrodt PLC shrugged off monetary claims brought by states in a sprawling generic drug antitrust enforcement action when the company emerged from bankruptcy in 2022.
February 19, 2026
A Connecticut federal judge has once again rejected generic-drug makers' bid to escape a multistate lawsuit accusing them of engaging in an overarching antitrust conspiracy, saying the evidence supports the need for a jury trial on whether the companies colluded to fix prices and divvy up markets for dozens of generic drugs.